Microbicides 2004

Microbicides 2004

Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411

02062 THREE DESIGN ISSUES

02073 LUBRICANTS CONTAINING N-9 MAY ENHANCE RECTAL TRANSMISSION OF HIV AND OTHER STI’S

02092_1 AN OPEN PHASE 1 TRIAL OF 13% CELLULOSE ACETATE PHTHALATE (CAP) VAGINAL MICROBICIDE.

02092_2 MAGNETIC RESONANCE IMAGING STUDY OF THE DISTRIBUTION AND RETENTION OF DEXTRIN SULPHATE

02340 FEASIBILITY OF CONDUCTING MICROBICIDE PREPAREDNESS STUDIES IN URBAN & RURAL KWAZULU-NATAL

02344 MULTIVARIATE ANALYSIS OF RISK FACTORS FOR HIV SEROCONVERSION IN THE COL-1492 PHASE III TRIAL

02345 RISK FACTORS ASSOCIATED WITH HIV INFECTION IN URBAN AND RURAL POPULATIONS OF SOUTH AFRICA

02351 DISPOSABLE UNIT-DOSE VAGINAL APPLICATOR DEVELOPMENT

02353 POTENTIAL PREVENTION OF HIV BY USING THE NEW CERVICAL BARRIER “FEMCAP” WITH MICROBICIDES

02407 VAGINAL FLORA CHARACTERISTICS OF HIV+ WOMEN ENROLLED IN A PHASE I CELLULOSE SULFATE STUDY: HPTN 049

02420_2 OPTIMAL ANALYSIS OF MRI DATA TO QUANTITATE THE DISTRIBUTION OF A VAGINAL PRODUCT

02433 ENROLLMENT FAILURES IN HIV+ AND HIV- WOMEN SCREENED FOR 2 PHASE I MICROBICIDE TRIALS: HPTN 049/050

02434 CHALLENGES IN THE RECRUITMENT OF HIV+ AND HIV- WOMEN IN US VAGINAL MICROBICIDE TRIALS: HPTN 049/050

02463_2 ACCEPTABILITY OF CARRAGUARD® AMONG HIV-INFECTED WOMEN AND MEN IN A SAFETY TRIAL IN SOUTH AFRICA

02496 PHASE I 14-DAY SAFETY AND ACCEPTABILITY STUDY OF 6% CELLULOSE SULFATE

02576 RECRUITMENT FOR A TRIAL OF MICROBICIDE SAFETY AND ACCEPTABILITY AMONG HIV-INFECTED WOMEN, THAILAND

02577_1 EVALUATION OF HIV-INFECTED WOMEN SCREENED FOR A CLINICAL TRIAL OF MICROBICIDE SAFETY, THAILAND

02577_2 CLINICAL TRIAL OF MICROBICIDE SAFETY AND ACCEPTABILITY AMONG HIV-INFECTED WOMEN IN NORTHERN THAILAND

02586 HIGH RATES OF CO-MORBID CONDITIONS & PELVIC FINDINGS IN HIV+ WOMEN ENROLLED IN HPTN049

02588 PARTIAL USE OF COLPOSCOPY IN THE SAFETY EVALUATION OF A CANDIDATE MICROBICIDE

02593 DETECTION OF HIV-1 RNA LOADS IN THE PRESENCE OF MICROBICIDE FORMULATIONS INTENDED FOR HUMAN USE

02597 EXPANDED PHASE I SAFETY AND ACCEPTABILITY TRIAL OF 6% CELLULOSE SULPHATE GEL AS A VAGINAL MICROBICIDE

02604 IMPACT OF CERVICOVAGINAL SECRETIONS ON HERPES SIMPLEX VIRUS (HSV) INFECTION

02609 THE HEC PLACEBO: DESIGNED FOR “NO EFFECT”

02613 CLINICAL SAFETY AND ACCEPTABILITY OF IOCIDE VAGINAL GEL

02614 VALIDITY AND FEASIBILITY OF SELF-SAMPLING FOR REPRODUCTIVE TRACT INFECTIONS IN SOUTH AFRICAN WOMEN

02615 UNDERSTANDING THE ACCEPTABILITY OF SELF-SAMPLING METHODS FOR REPRODUCTIVE TRACT INFECTIONS IN SOUTH AFRICAN WOMEN

02618_2 CLINICAL SAFETY EVALUATION OF MICROBICIDE APPLICATORS

02624 MINIMALLY INVASIVE ASSESSMENT OF MUCOSAL INFLAMMATION USING RECTAL SWABS

02640 CHALLENGES OF IMPLEMENTING QUALITY MANAGEMENT IN CLINICAL RESEARCH IN URBAN AND RURAL SOUTH AFRICA

02641 SEXUALLY TRANSMITTED INFECTIONS AMONG A COHORT OF FEMALES IN A MICROBICIDE FEASIBILITY STUDY

02645 DO SITE FEASIBILITY STUDIES CONTRIBUTE TO THE PLANNING OF PHASE III MICROBICIDE TRIALS?

02652 INHIBITORY EFFECT OF VAGINAL MICROBICIDES ON MOLECULAR AMPLIFICATION ASSAYS

02661 CHARACTERISATION OF RECENTLY TRANSMITTED HIV-1 VARIANTS IN SUBTYPE C INFECTED WOMEN

02676_2 ACCEPTABILITY OF CARRAGUARD AMONG HETEROSEXUAL COUPLES IN A SIX-MONTH CLINICAL TRIAL IN THAILAND

02679 HIV-1 RNA IN RECTAL MUCOSA SECRETIONS AND SEMINAL PLASMA; CONSIDERATIONS FOR MICROBICIDE EFFICACY

02699 A STUDY WITH THREE IMAGING TECHNIQUES OF VAGINAL GEL DISTRIBUTIONS